iNtRON Biotechnology, Inc. (048530.KQ)
KRW 5500.0
(-4.35%)
KRW 5500.0
(-4.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -40.58 Billion KRW | -843.29% |
| 2022 | 5.46 Billion KRW | 118.56% |
| 2021 | -29.41 Billion KRW | 40.52% |
| 2020 | -49.45 Billion KRW | -47.48% |
| 2019 | -33.53 Billion KRW | -97.35% |
| 2018 | -16.99 Billion KRW | -51.66% |
| 2017 | -11.2 Billion KRW | 31.63% |
| 2016 | -16.38 Billion KRW | -166.69% |
| 2015 | -6.14 Billion KRW | 0.0% |
| 2012 | -3.03 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -40.28 Billion KRW | 8.09% |
| 2024 Q1 | -43.82 Billion KRW | -7.99% |
| 2023 Q3 | -51.74 Billion KRW | 3.59% |
| 2023 Q1 | 1.02 Billion KRW | -81.17% |
| 2023 FY | -40.58 Billion KRW | -843.29% |
| 2023 Q2 | -53.66 Billion KRW | -5318.96% |
| 2023 Q4 | -40.58 Billion KRW | 21.56% |
| 2022 FY | 5.46 Billion KRW | 118.56% |
| 2022 Q4 | 5.46 Billion KRW | 175.1% |
| 2022 Q3 | -7.27 Billion KRW | 82.18% |
| 2022 Q2 | -40.79 Billion KRW | -53.85% |
| 2022 Q1 | -26.51 Billion KRW | 9.85% |
| 2021 Q3 | -31.99 Billion KRW | 46.83% |
| 2021 Q4 | -29.41 Billion KRW | 8.08% |
| 2021 FY | -29.41 Billion KRW | 40.52% |
| 2021 Q1 | -61.05 Billion KRW | -22.36% |
| 2021 Q2 | -60.18 Billion KRW | 1.43% |
| 2020 FY | -49.45 Billion KRW | -47.48% |
| 2020 Q1 | -32.13 Billion KRW | 16.66% |
| 2020 Q4 | -49.89 Billion KRW | -6.73% |
| 2020 Q3 | -46.75 Billion KRW | -14.12% |
| 2020 Q2 | -40.96 Billion KRW | -27.46% |
| 2019 Q3 | -38.96 Billion KRW | 7.65% |
| 2019 FY | -33.53 Billion KRW | -97.35% |
| 2019 Q1 | -13.24 Billion KRW | 22.02% |
| 2019 Q4 | -38.56 Billion KRW | 1.03% |
| 2019 Q2 | -42.18 Billion KRW | -218.41% |
| 2018 Q4 | -16.99 Billion KRW | -85.2% |
| 2018 FY | -16.99 Billion KRW | -51.66% |
| 2018 Q3 | -9.17 Billion KRW | -17.99% |
| 2018 Q2 | -7.77 Billion KRW | 15.17% |
| 2018 Q1 | -9.16 Billion KRW | 18.18% |
| 2017 Q1 | -14.13 Billion KRW | 13.73% |
| 2017 FY | -11.2 Billion KRW | 31.63% |
| 2017 Q4 | -11.2 Billion KRW | 2.97% |
| 2017 Q3 | -11.54 Billion KRW | 15.2% |
| 2017 Q2 | -13.61 Billion KRW | 3.69% |
| 2016 Q4 | -16.38 Billion KRW | 0.0% |
| 2016 Q1 | 13.73 Billion KRW | 0.0% |
| 2016 FY | -16.38 Billion KRW | -166.69% |
| 2015 FY | -6.14 Billion KRW | 0.0% |
| 2013 Q3 | 604.62 Million KRW | -74.32% |
| 2013 Q2 | 2.35 Billion KRW | 29.3% |
| 2013 Q1 | 1.82 Billion KRW | 160.07% |
| 2012 FY | -3.03 Billion KRW | 0.0% |
| 2012 Q4 | -3.03 Billion KRW | -51.91% |
| 2012 Q3 | -1.99 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 12.122% |
| BINEX Co., Ltd. | 45.34 Billion KRW | 189.497% |
| Bioneer Corporation | -3.9 Billion KRW | -938.561% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | 585.941% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | 373.956% |
| CrystalGenomics, Inc. | 8.99 Billion USD | 551.348% |
| Helixmith Co., Ltd | -24.42 Billion KRW | -66.155% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 110.435% |
| Medy-Tox Inc. | 49.58 Billion KRW | 181.85% |
| Peptron, Inc. | 4.86 Billion KRW | 933.598% |
| Amicogen, Inc. | 125.26 Billion KRW | 132.4% |
| Genexine, Inc. | 61.39 Billion KRW | 166.104% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | -196.525% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 27.596% |
| ALTEOGEN Inc. | 53.56 Billion KRW | 175.76% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | -23.214% |
| SillaJen, Inc. | -13.89 Billion KRW | -192.154% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 148.155% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | 248.256% |
| Genomictree Inc. | -43.43 Billion KRW | 6.562% |
| MedPacto, Inc. | -64 Billion KRW | 36.587% |
| D&D Pharmatech | -7.5 Billion KRW | -440.568% |
| EASY BIO,Inc. | 53.21 Billion KRW | 176.272% |
| GI Innovation, Inc. | -4.82 Billion KRW | -741.57% |